EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer

Summary

This clinical trial is studying the amount of EF5 and motexafin lutetium present in tumor cells and/or normal tissues of patients with abdominal (such as ovarian, colon, or stomach cancer) or non-small cell lung cancer. EF5 may be effective in measuring oxygen in tumor tissue. Photosensitizing drugs such as motexafin lutetium are absorbed by tumor cells and, when exposed to light, become active and kill the tumor cells. Knowing the level of oxygen in tumor tissue and the level of motexafin lutetium absorbed by tumors and normal tissue may help predict the effectiveness of anticancer therapy

Conditions

• Advanced Adult Primary Liver Cancer
• Carcinoma of the Appendix
• Fallopian Tube Cancer
• Gastrointestinal Stromal Tumor
• Localized Extrahepatic Bile Duct Cancer
• Localized Gallbladder Cancer
• Localized Gastrointestinal Carcinoid Tumor
• Localized Resectable Adult Primary Liver Cancer
• Localized Unresectable Adult Primary Liver Cancer
• Metastatic Gastrointestinal Carcinoid Tumor
• Ovarian Sarcoma
• Ovarian Stromal Cancer
• Primary Peritoneal Cavity Cancer
• Recurrent Adult Primary Liver Cancer
• Recurrent Adult Soft Tissue Sarcoma
• Recurrent Colon Cancer
• Recurrent Extrahepatic Bile Duct Cancer
• Recurrent Gallbladder Cancer
• Recurrent Gastric Cancer
• Recurrent Gastrointestinal Carcinoid Tumor
• Recurrent Non-small Cell Lung Cancer
• Recurrent Ovarian Epithelial Cancer
• Recurrent Ovarian Germ Cell Tumor
• Recurrent Pancreatic Cancer
• Recurrent Rectal Cancer
• Recurrent Small Intestine Cancer
• Recurrent Uterine Sarcoma
• Regional Gastrointestinal Carcinoid Tumor
• Small Intestine Adenocarcinoma
• Small Intestine Leiomyosarcoma
• Small Intestine Lymphoma
• Stage 0 Non-small Cell Lung Cancer
• Stage I Adult Soft Tissue Sarcoma
• Stage I Colon Cancer
• Stage I Gastric Cancer
• Stage I Non-small Cell Lung Cancer
• Stage I Ovarian Epithelial Cancer
• Stage I Ovarian Germ Cell Tumor
• Stage I Pancreatic Cancer
• Stage I Rectal Cancer
• Stage I Uterine Sarcoma
• Stage II Adult Soft Tissue Sarcoma
• Stage II Colon Cancer
• Stage II Gastric Cancer
• Stage II Non-small Cell Lung Cancer
• Stage II Ovarian Epithelial Cancer
• Stage II Ovarian Germ Cell Tumor
• Stage II Pancreatic Cancer
• Stage II Rectal Cancer
• Stage II Uterine Sarcoma
• Stage III Adult Soft Tissue Sarcoma
• Stage III Colon Cancer
• Stage III Gastric Cancer
• Stage III Ovarian Epithelial Cancer
• Stage III Ovarian Germ Cell Tumor
• Stage III Pancreatic Cancer
• Stage III Rectal Cancer
• Stage III Uterine Sarcoma
• Stage IIIA Non-small Cell Lung Cancer
• Stage IIIB Non-small Cell Lung Cancer
• Stage IV Adult Soft Tissue Sarcoma
• Stage IV Colon Cancer
• Stage IV Gastric Cancer
• Stage IV Non-small Cell Lung Cancer
• Stage IV Ovarian Epithelial Cancer
• Stage IV Ovarian Germ Cell Tumor
• Stage IV Pancreatic Cancer
• Stage IV Rectal Cancer
• Stage IV Uterine Sarcoma
• Unresectable Extrahepatic Bile Duct Cancer
• Unresectable Gallbladder Cancer

Interventions

DRUG

EF5

Given IV

DRUG

motexafin lutetium

Given IV

OTHER

pharmacological study

Correlative studies

Sponsors & Collaborators

• National Cancer Institute (NCI)

  lead NIH

Principal Investigators

• Stephen Michael Hahn · Abramson Cancer Center at Penn Medicine

Study Design

Allocation

NA

Purpose

DIAGNOSTIC

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2004-05-31

Primary Completion

2006-01-31

Countries

• United States

Study Locations